This year marks ten years since the MHRA joined seven other global regulators to establish the ICMRA to address the need for strong global cooperation and alignment in the regulation of medicinal products.
ICMRA's greatest achievement over the past decade has been the leadership of its members working together during the COVID-19 pandemic. As the first ICMRA member to approve COVID-19 vaccine developed by Pfizer/BioNTech for use in the UKthe MHRA worked alongside other members to accelerate and optimize the development and approval of COVID-19 vaccines and treatments and helped increase the efficiency and effectiveness of regulatory processes and decision-making.
The UK's leadership in monitoring the safety of Covid-19 vaccines was also shared through ICMRA and supported their safe use around the world.
Dr June Raine, Chief Executive of MHRA, said:
โOver the past ten years, as a founding member of ICMRA, we have demonstrated how international collaboration can address major health challenges around the world.
"Through strong collaboration across ICMRA, we can share our national knowledge for global impact, supporting streamlined regulatory processes and ensuring patients around the world have access to safe and effective healthcare products."
Over the last decade, the MHRA and other ICMRA members have supported the work of regulators around the world in important milestonesfrom the fight against antimicrobial resistance to topics such as clinical trials, pharmacovigilance, regulatory convergence and dependency, innovation, real-world evidence and alignment in the global response to COVID-19.
In the coming years, the MHRA will continue to support the ICMRA to address current and emerging regulatory and safety challenges in human medicine, strengthen collaboration and communication, and improve the quality, safety and effectiveness of medicines for the benefit of patients. of all the world.
The MHRA will join its fellow ICMRA members, now numbering 38, to celebrate its 10th anniversary at its annual meeting. Summit and Plenary in Melbourne from November 13 to 16.
During the summit, the MHRA will engage in discussions on key global regulatory issues and challenges, including the use of artificial intelligence and machine learning, the evolution of clinical trials and advanced medical products based on genes, cells or tissue engineering.
Know more
Notes to editors
-
You can consult the statement from the European Medicines Agency here.
-
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK ensuring that they work and are acceptably safe. All of our work is backed by strong, fact-based judgment to ensure the benefits justify any risks.
-
The MHRA is an executive agency of the Department of Health and Social Care.
-
For media inquiries, please contact newscenter@mhra.gov.uk or 020 3080 7651.
